GB0206792D0 — Normoglycemia
Assigned to Katholieke Universiteit Leuven · Expires 2002-05-01 · 24y expired
What this patent protects
A control system is described for use with a system configured to maintain normoglycemia in a subject under a condition of insulin resistance or under a condition of increased glucose turnover, the system having a sensor to measure glycemia level in a subject and a programmable a…
USPTO Abstract
A control system is described for use with a system configured to maintain normoglycemia in a subject under a condition of insulin resistance or under a condition of increased glucose turnover, the system having a sensor to measure glycemia level in a subject and a programmable actuator to delivery a blood glucose regulator to said subject, wherein the control system is configurable to adapt the administration levels of the blood glucose regulator to a desired glycemia level in said subject, the control system comprising an adaptive model; - wherein the adaptive model is configurable so that in the initial phase it is based on the factors patient profile and on-admission parameters that determine an initial model and in a later phase on factors that influence the dynamic behaviour of the patient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.